Search Results 1681-1690 of 19649 for Hemoglobin

1. A Study to Evaluate AL101 Monotherapy in Patients with Notch Activated Triple Negative Breast Cancer - Mayo Clinic

   hemoglobin < 8 g/dL;; total bilirubin > 1.5 upper limit of normal (ULN) (except known Gilbert's syndrome whereby the total bilirubin must be < 5 mg/dL); ...

2. A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular Carcinoma - Mayo Clinic

   Hemoglobin 9 g/dL. Acceptable blood sugar control: Fasting glucose < 160 mg/dL (CTCAE grade 1 baseline). Urinalysis: No clinically significant abnormalities ...

3. A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT - Mayo Clinic

   - Hemoglobin ≥ 8.0 g/dL (may receive red blood cell [RBC] transfusions) (within 7 days prior to enrollment). - Creatinine clearance or radioisotope ...

4. A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL without packed red blood cell (PRBC) transfusion in the prior 21 days;; Serum creatinine ≤ 1.5 x upper limit of normal (ULN); ...

5. A Phase 2, Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia with and without Red Blood Cell-Transfusion Dependence - Mayo Clinic

   No subjects with an interval ≥ 42 days between hemoglobin measurements will be enrolled;; There must not be any RBC transfusions within the 84-day period ...

6. Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia - Mayo Clinic

   ... hemoglobin < 11 g/dL) or thrombocytopenia (platelet count < 100 x 10^9/L) that is not attributable to autoimmune hemolytic anemia or thrombocytopenia.

7. A Study to Evaluate the Safety and Effectiveness of BMS-986036 (pegbelfermin) in Adults with Nonalcoholic Steatophepatitis (NASH) and Compensated Liver Fibrosis - Mayo Clinic

   Hemoglobin A1c ≥10%;; Fasting TGs > 500 mg/dL;; Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 according to the Modification of Diet in ...

8. Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - Mayo Clinic

   Participation eligibility · Evidence of progressive marrow failure as manifested by the development of worsening anemia (hemoglobin [Hg] < 11 g/dl) and/or ...

9. A Study of BBI608 Combined with Standard Chemotherapies in Adult Patients who have Pancreatic Cancer - Mayo Clinic

   Hemoglobin (Hgb) ≥ 9 g/dl; Absolute neutrophil count ≥ 1.5 x 10^9/L; Platelets ≥ 100 x 10^9/L; Acceptable coagulation studies as demonstrated by prothrombin ...

10. Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer - Mayo Clinic

    * REGISTRATION: Hemoglobin \>= 9.0 g/dL (obtained =\< 30 days prior to registration) * REGISTRATION: Platelet count \>= 100,000/mm\^3 (obtained =\< 30 days ...